11572 RESULTS
COMMENT In most earlier studies, CSF p-tau181 concentration has not been associated with tau tangle pathology as determined by tau PET or neuropathological examination, although one study from the Swedish BioFINDER study found weak correlations between CSF p-tau1
COMMENT The amyloid-negative (A-)/flortaucipir (FTP) medial temporal lobe (MTL)-positive (FTP-MTL+) group has not previously received attention, and the current report helped to fill that gap nicely. This is a well-done and clearly written piece that makes the po
COMMENT The editorial by Landau and Mormino very nicely summarizes the key “takeaways” of this study by Costoya-Sanchez et al. The study recapitulates some conclusions based on clinicopathological work published by my colleague, Joseph L. Price, and me many years
COMMENT I do have several concerns about the Quest direct-to-consumer test. Below are just some of them. First, there is no published data on the test’s performance or how the cutoffs were determined. Other blood tests that are currently clinically available, alb
COMMENT This is a very worrying development, and may harm the process of implementation of blood-based biomarkers. As the Dutch saying goes, “Trust arrives on foot, but leaves on horseback.” The lack of any data is a very serious problem. Even if the assay is sim
COMMENT That this test is being marketed directly to consumers tells us that people are worried about Alzheimer’s disease, and that they don’t always want to work through their regular doctor. This is complicated by the fact that many primary care doctors aren’t
COMMENT I am against offering a direct-to-consumer Aβ42/40 blood test for individuals to initiate themselves without oversight by an experienced AD provider, who has formally evaluated the person for AD and other potential neurological conditions in several stand
COMMENT I am generally against screening of healthy populations, unless rigorous science has shown that such screening approaches result in more good than harm. To do that, large-scale, population-based prospective studies are needed. Such studies should show tha
COMMENT This is clearly not a good idea. Aside from a far from satisfactory sensitivity and specificity, which leaves far too much room for false-negative and false-positive results, it is also in contrast to what the AD community has always voiced very clearly:
COMMENT Congratulations on a very nice paper confirming in humans what Thomas Wisniewski's and our labs have been study for decades in vitro and in mice, that is, the catalytic activity of apoE4 on amyloid formation and consequent cognitive decline. We and c
COMMENT Much like the research upon exercise and changes in cognitive ability, the at-home testing in research is extremely different from the at-home testing done without research supervision. The presence of a spouse during testing invalidates many, if not most
COMMENT These extremely exciting and important studies provide new information about the time course of proteomic changes associated with predisposition to, and clinical progression of, autosomal dominant Alzheimer’s disease (ADAD) and sporadic AD. The papers ill
COMMENT The proteomics analysis performed in this paper, on CSF collected as part of the DIAN study, is a tour de force. There are a number of intriguing findings. I was very interested by the finding that certain protein levels differed between the mutation carr
COMMENT This ADAD CSF proteomic study is an asset to the AD community as it’s based on a collection of samples over the course of six decades. The authors showed changes in proteins from CSF associated with biomarker and pathological changes of AD. Especially pro
COMMENT This new DIAN study is indeed fascinating. There has been prior research suggesting that glycolytic metabolism is specifically altered early in Alzheimer's disease. What makes studies like these in autosomal-dominant Alzheimer's disease highly i
